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Abstract
Background: Trans fatty acids are produced either by industrial hydrogenation or by biohydrogenation in the rumens of
cows and sheep. Industrial trans fatty acids lower high-density lipoprotein (HDL) cholesterol, raise low-density lipoprotein
(LDL) cholesterol, and increase the risk of coronary heart disease. The effects of trans fatty acids from ruminants are less
clear. We investigated the effect on blood lipids of cis-9, trans-11 conjugated linoleic acid (CLA), a trans fatty acid largely
restricted to ruminant fats.
Methodology/Principal Findings: Sixty-one healthy women and men were sequentially fed each of three diets for three
weeks, in random order, for a total of nine weeks. Diets were identical except for 7% of energy (approximately 20 g/day),
which was provided either by oleic acid, by industrial trans fatty acids, or by a mixture of 80% cis-9, trans-11 and 20% trans-
10, cis-12 CLA. After the oleic acid diet, mean (6 SD) serum LDL cholesterol was 2.6860.62 mmol/L compared to
3.0060.66 mmol/L after industrial trans fatty acids (p,0.001), and 2.9260.70 mmol/L after CLA (p,0.001). Compared to
oleic acid, HDL-cholesterol was 0.0560.12 mmol/L lower after industrial trans fatty acids (p = 0.001) and 0.0660.10 mmol/L
lower after CLA (p,0.001). The total-to–HDL cholesterol ratio was 11.6% higher after industrial trans fatty acids (p,0.001)
and 10.0% higher after CLA (p,0.001) relative to the oleic acid diet.
Conclusions/Significance: High intakes of an 80:20 mixture of cis-9, trans-11 and trans-10, cis-12 CLA raise the total to HDL
cholesterol ratio in healthy volunteers. The effect of CLA may be somewhat less than that of industrial trans fatty acids.
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Introduction
Trans fatty acids arise from industrial hydrogenation, and from
biohydrogenation in ruminant animals. Industrial trans fatty acids
are produced by partial hydrogenation of vegetable and fish oils.
Such industrial trans fatty acids raise the total to HDL cholesterol
ratio in blood and the risk of coronary heart disease [1–5].
Industrial and ruminant fats contain mostly the same species of
trans fatty acids, but in different proportions. The major isomers in
industrial trans are trans-9 18:1 (elaidic acid) and trans-10 18:1, plus
smaller amounts of trans-8 18:1 and trans-11 18:1. In milk and meat
the predominant trans fatty acid is trans-11 18:1 (vaccenic acid). In
addition, ruminant fats contain small amounts of cis-9, trans-11
18:2 (conjugated linoleic acid, abbreviated to CLA in this paper
unless otherwise mentioned). CLA is also formed from ingested
vaccenic acid in animals and in humans [6]. The proportion of
CLA in industrially hydrogenated fats is negligible, but mixtures of
cis-9, trans-11 and trans-10, cis-12 CLA are produced industrially
and sold as supplements.
In rodents, such mixtures of cis-9, trans-11 and trans-10, cis-12
CLA isomers improved blood lipid profiles, decreased body
fatness, improved insulin sensitivity, and reduced cancer and
atherosclerosis risk [7]. When the isomers were studied separately,
cis-9, trans-11 CLA improved blood lipid profile both in hamsters
and mice, whereas trans-10, cis-12 CLA did not affect the blood
lipid profile or worsened it [8,9]. Many of the effects of CLA found
in rodents have not been reproduced in other species, including
humans. Human studies of the effects of CLA mixtures and of
separate cis-9, trans-11 and trans-10, cis-12 CLA isomers on lipid
profile, weight loss, and insulin resistance have been inconclusive
[10,11]. Most of these studies were uncontrolled trials using CLA
supplements. Two controlled dietary intervention studies with
diets naturally enriched with cis-9, trans-11 CLA also did not
provide convincing findings, although the ratio of LDL to HDL
cholesterol tended to go up on CLA [12,13].
Nevertheless, CLA is sold widely as a supplement, and levels of
cis-9, trans-11 CLA in ruminant fats have been increased on
purpose by altering the animals’ feed [14]. We now studied the
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effects of high doses of cis-9, trans-11 CLA on lipoprotein levels in a
randomized trial in humans.
Methods
Ethics Statement
The Medical Ethics Committee of Wageningen University
approved the aim and design of the study, which was registered in
the NIH clinical trial database (ClinicalTrials.gov number.
NCT00529828). The protocol for this trial and supporting
CONSORT checklist are available as supporting information;
see Checklist S1 and Protocol S1.
Subjects
We recruited subjects aged 18 to 65 through advertisements in
the Wageningen area. Suitable candidates provided written
informed consent before screening. We excluded subjects with
glycosuria and proteinuria and with concentrations of total
cholesterol higher than 6.5 mmol/L or triglycerides higher than
2.3 mmol/L in serum. Subjects were also excluded if they suffered
from diabetes or cardiovascular disease, if they used cholesterol
lowering or anti-hypertensive medication, had unusual dietary
habits including high alcohol intakes, had a body mass index
(BMI) .30 kg/m2, or were pregnant or lactating.
Study Design
Our objective was to investigate the effects of cis-9, trans-11 CLA
on serum lipid and lipoprotein concentrations relative to the cis-
monounsaturated fatty acid oleic acid (cis-9 18:1). A diet rich in
industrial trans fatty acids was provided as a positive control as
these are known to raise LDL-cholesterol in comparison with oleic
acid. The study was a controlled single blind randomized multiple
crossover trial with three consecutive periods of 21 days. The trial
ran from September 25 to November 27, 2007. The trial was
designed to detect a significant (p,0.05) effect of CLA versus oleic
acid on LDL-cholesterol with a power of 80% if the real
population effect exceeded 0.13 mmol/L, which is half the effect
expected for industrial trans fatty acids [15,16]. Subjects were
randomly divided over all 6 possible diet sequences by an
independent researcher using computer-generated numbers.
The study was executed according to methods previously
described [17]. We estimated the habitual energy intake of the
subjects with a food frequency questionnaire [18]. Diets were
designed for 14 levels of energy intake, from 7 to 20 MJ/day, and
subjects were allocated to an intake level close to their habitual
energy intake. Macronutrients, cholesterol and fiber intakes were
based on Dutch nutrition guidelines. On weekdays, subjects
consumed a hot meal at lunchtime under our supervision at the
metabolic kitchen and dining room of Wageningen University. All
other food was provided daily to take away. The supplied foods
provided 90% of each subjects’ energy requirement. For the
remaining 10%, subjects were free to select favorite foods low in
fat from a restricted list, which they recorded in a diary. Subjects
recorded illnesses, use of medication and any deviations from the
diet. We weighed subjects twice a week and adjusted energy intake
if bodyweight changed by more than 1 kg. Subjects were asked to
maintain their usual pattern of physical activity, and they were not
allowed to drink fortified fruit juices, types of coffee that raise
cholesterol [19] or to eat more than 10 pieces of liquorice candy a
day.
Study Diets
The diets were intended to be identical except for 7% of total
energy as CLA, industrial trans fatty acid or oleic acid (Table 1).
CLA was provided by a CLA-rich oil (donated by Lipid Nutrition,
Wormerveer, The Netherlands) The oil consisted of triglycerides;
78% of the trans fatty acids in it was the cis-9, trans-11 CLA isomer
found in ruminant fat, 17% the trans-10, cis-12 CLA isomer and
5% other trans fatty acids. Before the study started we performed a
safety study in 19 other volunteers. They received 28.9 g CLA-rich
oil per day for 3 weeks under strict medical supervision. We found
that the treatment had no adverse effects on liver and kidney
function tests or other outcomes [20].
NIZO Food Research (Ede, The Netherlands) manufactured
margarines and yoghurt drinks enriched with the special oils and
fats to our specifications. The fat in the oleic acid margarine
consisted of 82% high-oleic sunflower oil (Aldoc BV, Schiedam,
The Netherlands) and 18% of a standard hard stock, an
interesterified mixture of palm oil and palm kernel fat (Unilever
Research & Development, Vlaardingen, The Netherlands). The
fat in the CLA margarine contained 25% CLA-rich oil, 10%
sunflower oil, 47% high-oleic sunflower oil and 18% standard
hard stock, and the fat of the industrial trans margarine consisted
of 65% partially hydrogenated vegetable fat (Melano, FUJI Oil
Europe, Gent, Belgium), 10% sunflower oil and 25% high-oleic
sunflower oil. In addition, yoghurt drinks were produced by
enriching fat-free yoghurt with 5 g high oleic sunflower oil, 5 g
CLA-rich oil or 5 g partially hydrogenated vegetable fat per
Table 1. Fatty acid composition of the oils and fats used to produce the experimental margarines and yoghurts.1
High-oleic sunflower oil Partly hydrogenated vegetable fat CLA-rich oil
g/100 g fatty acids
Saturated fatty acids 8.360.1 43.460.6 7.760.9
Total cis fatty acids 90.060.9 15.560.2 15.860.2
- Cis-9 C18:1(oleic acid) 81.960.9 11.160.2 13.460.1
- Cis-9,cis-12 C18:2 (linoleic acid) 7.660.0 0.360.0 2.260.1
Total trans fatty acids (other than CLA) 0.360.4 38.960.1 0.860.9
Total CLA 0.060.0 0.260.1 73.760.6
- Cis-9,trans-11 CLA 0.060.0 0.060.0 56.960.4
- Trans-10,cis-12 CLA 0.060.0 0.060.0 12.860.0
1CLA, Conjugated Linoleic Acid.
Fatty acid composition (means 6 SD) from analyses of one sample taken before and one sample taken after the study.
doi:10.1371/journal.pone.0009000.t001
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100 ml, respectively. The margarines were used as a spread, and
as an ingredient in bread, cookies, sauces, and gravies. We bought
other food items commercially.
Diet Composition
Duplicate diets were collected daily; they were stored at 220uC
and analyzed for protein, fat, fatty acids, dry matter, ash, dietary
fiber and digestible carbohydrate [21–23]. CLA isomers were
separated by gas chromatography on a Sil-88 column and other
fatty acids on a WAX-58 column (Varian, Middelburg, The
Netherlands). The nutrients in the free-choice items were
calculated (NEVO, 2006) and added to the analyzed values.
Blood Measurements
We took blood samples after an overnight fast on days 19 and
21 of each of the three diet periods and stored serum and plasma
at 280uC. Samples were taken at the same time on every blood-
sampling day to minimize within-subject variation. All six blood
samples of one subject were analyzed within the same run to
eliminate interassay variation. Fatty acids in plasma cholesteryl
esters were analyzed in the samples taken on day 19 of each period
as described above [24]. The results for CLA isomers and other
fatty acids were combined and expressed as a proportion by weight
of all fatty acids detected. Apolipoprotein B was measured on a
Behring Nephelometer Analyzer II (Dade Behring, Marburg,
Germany) in EDTA plasma pooled per subject per period. Total
and HDL-cholesterol and triglycerides were determined enzymat-
ically on a Synchron LX20 (Beckman Coulter, Mijdrecht, The
Netherlands), LDL-cholesterol was calculated [25].
Statistical Analysis
We defined the outcome variables and the statistical analysis
scripts in detail before the results of the measurements were
known. Treatment codes were broken after data-analysis was
completed. For each subject, blood lipid outcomes were averaged
for the two blood samples per diet. All data are reported as mean
6 standard deviation (SD), 95% confidence interval, or % change
compared to reference group. Data were analyzed by the mixed
linear model procedure in SPSS version 15.0 (SPPS, Chicago, Ill)
with serum lipids as dependent and diet and period as independent
variables. Carryover effects were tested by introducing a
treatment-by-period interaction term, and heterogeneous com-
pound symmetry was selected as covariance structure [26]. When
the analyses indicated a significant effect of diet (p,0.05), Least
Significant Difference t-test was used for pair wise comparisons of
the CLA and industrial trans fatty acids diets versus the control
oleic acid diet. After the codes had been broken we became aware
of the gender effect reported by Chardigny et al. [27]. We
therefore tested gender differences by including sex and a sex-by-
treatment interaction term in the model.
Results
Eighty-eight apparently healthy volunteers applied for enrol-
ment into the study (Figure 1). Nine withdrew before the pre-
study screening visit and 12 proved ineligible. Major reasons for
exclusion were elevated lipid levels (n = 3), high BMI (n = 2) and
unusual dietary habits (n = 2). Out of the 67 eligible volunteers, we
excluded four by lottery. Sixty-three apparently healthy subjects
started the study. One man withdrew at 6 days for personal
reasons and one woman at 20 days due to illness not related to the
study. Table 2 gives the baseline characteristics of the 61
participants who completed the study.
Diets and Dietary Adherence
The intake of total protein, fat, carbohydrates, alcohol,
cholesterol and dietary fiber did not differ between diets
(Table 3). At an energy intake of 11 MJ (2627 kcal) per day,
the CLA diet provided 26.8 g of CLA isomers, while the industrial
trans diet supplied 21.8 g of trans C18:1 per day.
The fatty-acid composition of plasma cholesteryl esters
confirmed the subjects’ adherence to the diets. At the end of the
Figure 1. Flow chart of a randomized cross-over trial of the effect of Conjugated Linoleic Acid (CLA) on lipoprotein levels in 61
healthy subjects. Each intervention period lasted 3 weeks; O, Oleic acid diet; I, Industrial trans fat diet; C, CLA diet. * 2 subjects dropped out early in
the study, one for personal reasons and one because of illness, both unrelated to the trial. These subjects were not included in the analysis.
doi:10.1371/journal.pone.0009000.g001
CLA and Lipoprotein Levels
PLoS ONE | www.plosone.org 3 February 2010 | Volume 5 | Issue 2 | e9000
oleic acid diet period, cis C18:1 fatty acids comprised 24.764.3 g/
100 g fatty acids. On the CLA and industrial trans diet this was
17.663.4 and 18.563.8 g/100 g, respectively. The sum of CLA
isomers in plasma cholesteryl esters was 4.861.4 g/100 g after the
CLA diet, 1.460.7 g/100 g after the oleic acid diet and
1.560.6 g/100 g after the industrial trans diet.
Diaries kept by the subjects revealed only minor deviations from
the protocol that were unlikely to affect outcomes. Six subjects
reported nausea for 1 or 2 days on the CLA and industrial trans
fatty acid diets, and 2 while on the oleic acid diet. Three reported
diarrhea for 1–2 days while on the CLA diet.
Over the 63 days of the trial, average body weight fell by
0.661.7 kg. Body weight at the end of the oleic acid diet differed
0.060.9 kg from that after the CLA diet and 20.160.9 kg from
that after the industrial trans fatty acid diet. Caloric intakes did not
differ between the 3 diets (p = 0.998).
Serum Lipids and Lipoproteins
The total trans fatty acid intake on the CLA diet was 1.6% of
energy higher than on the industrial trans fatty acid diet while the
saturated fatty acids intake was 2.5% of energy lower (Table 3).
In order to provide an unbiased comparison between industrial
trans fatty acids and CLA, we corrected the serum lipid responses
for these differences in intake using the equations of Mensink et al.
[16]. The corrected levels were only slightly different from the
original levels (Table 4), and the statistical significance of the
changes relative to oleic acid was the same whether we used
corrected or uncorrected levels.
The LDL-cholesterol level was 11.6% (p,0.001) higher after
the industrial trans diet and 8.7% (p,0.001) higher after the CLA
Table 3. Mean daily intakes of energy and nutrients according to chemical analysis of duplicates of the diets.1
Oleic acid diet Industrial trans diet CLA diet
Energy intake (MJ/day) 10.6 10.8 10.7
Kcal/day 2532 2568 2553
Fat (% of energy) 39.7 40.1 39.7
Saturated fatty acids 10.5 13.8 11.3
- C12:0 (lauric) 0.7 0.2 0.8
- C14:0 (myristic) 0.9 0.7 1.1
- C16:0 (palmitic) 5.7 9.7 6.3
- C18:0 (stearic) 2.0 2.3 1.9
Total cis fatty acids 27.4 17.1 17.7
- Cis-9 C18:1 (oleic) 23.1 11.3 13.4
- Cis-9,cis-12 C18:2 (linoleic) 3.2 4.1 3.4
Total trans fatty acids 0.2 7.5 9.1
- Total trans C18:1 ,0.1 7.3 ,0.1
- Trans-9 C18:1(elaidic) ,0.1 3.1 ,0.1
- Trans-10 C18:1 ,0.1 1.5 ,0.1
- Trans-11 C18:1(vaccenic) ,0.1 0.8 ,0.1
- Total CLA 0.1 0.1 9.0
- Cis-9,trans-11 CLA 0.1 0.1 6.9
- Trans-10,cis-12 CLA 0.0 0.0 1.5
Protein (% of energy) 12.6 11.8 12.8
Carbohydrates (% of energy) 46.3 46.7 46.0
Alcohol (% of energy) 1.4 1.4 1.5
Dietary fiber (g/MJ) 3.0 2.9 2.9
Cholesterol (mg/MJ) 22.3 22.8 21.9
1CLA, Conjugated Linoleic Acid.
The nutrients of the free-choice low fat items (less than 10 energy percent) were calculated (NEVO, 2006) and added to the analyzed values.
doi:10.1371/journal.pone.0009000.t003
Table 2. Baseline characteristics at the pre-study screening of
all subjects who completed the study (n = 61).
Characteristics
Age (yr) 30.9613.71
Gender: male (n) 25 (41%)2
Height (m) 1.7560.09
Weight (kg) 70.2612.5
Body Mass Index (kg/m2) 22.863.2
Energy intake (MJ/d) 10.363.3
Total cholesterol (mmol/L) 4.5460.77
HDL-cholesterol (mmol/L) 1.3160.36
LDL-cholesterol (mmol/L) 2.8760.68
Total to HDL cholesterol ratio 3.6660.96
LDL to HDL cholesterol ratio 2.3560.86
Serum triglycerides (mmol/L) 0.9860.45
1Values are means 6 SD.
2Values are numbers (n); percentage in parentheses.
doi:10.1371/journal.pone.0009000.t002
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diet than after the oleic acid diet (Table 4). LDL-cholesterol levels
were higher in 53 subjects after the CLA diet and in 55 subjects
after the industrial trans fatty acid diet. The ratio of total to HDL
cholesterol was 11.6% higher after the industrial trans fatty acid
diet (p,0.001), and 10.0% higher after the CLA diet (p,0.001).
The apolipoprotein B level was higher on both the industrial trans
(7.4%; p,0.001) and the CLA diet (4.7%; p,0.001). The level of
triglycerides was significantly higher after the industrial trans fatty
acid diet (16.1%; p,0.001) but not after the CLA diet (5.7%;
p= 0.085). The responses of blood lipids to industrial trans fatty
acids were close to those predicted by the Mensink equations [16].
For instance, we found an increase in LDL-cholesterol of
0.33 mmol/L uncorrected, or 0.31 mmol/L after correction,
while the equations predicted an increase of 0.35 mmol/L.
HDL-cholesterol decreased by 0.03 mmol/L uncorrected, or
0.05 mmol/L after correction, while the predicted decrease was
0.06 mmol/L.
We also compared the two types of trans fatty acids with each
other. After the industrial trans fatty acid diet the LDL-cholesterol
level was 2.6% higher than after CLA (p=0.049). Levels of serum
triglycerides (8.9%; p=0.004) and apolipoprotein B (2.5%; p=0.041)
were also higher after the industrial trans than after the CLA diet.
The effects of industrial trans and CLA on the total to HDL
cholesterol and the LDL to HDL cholesterol ratio did not differ
significantly. There were no important carry over or period effects.
Gender
In our study, men were more sensitive to the effects of trans fatty
acids than women. Sex-by-treatment interaction was found for the
total to HDL cholesterol ratio (p = 0.001), LDL to HDL
cholesterol ratio (p = 0.007), and triglyceride levels (p = 0.014).
After the CLA diet the ratio of total to HDL cholesterol was
0.5560.46 higher in men and 0.2060.27 higher in women
(p = 0.002 for difference) than on the oleic acid diet. The ratio of
LDL to HDL cholesterol was 0.4560.36 higher in men and
0.2060.23 higher in women (p= 0.003). On the industrial trans
fatty acid diet ratios also increased more in men than in women.
After the CLA diet triglyceride levels in men were 0.1660.34
higher and in women 0.0260.17 lower than on oleic acid.
Discussion
We found that a high intake of cis-9, trans-11 CLA plus a smaller
amount of trans-10, cis-12 CLA raised LDL-cholesterol and
lowered HDL-cholesterol levels in healthy humans. The effect of
CLA was somewhat less than that of industrial trans fatty acids.
Strengths and Limitations
Our study had several strengths. Food intake was strictly
controlled, the composition of the diet was verified by chemical
analysis, and adherence was evidenced by changes in blood fatty
Table 4. Mean (6 SD) values for serum lipid, lipoprotein cholesterol and apoB levels at the end of the three dietary periods
(n = 61), and means (95% Confidence Intervals) for individual differences between diets.1
Oleic acid diet
Industrial trans
diet uncorrected
Industrial
trans diet 2 CLA diet
Industrial trans 2
minus oleic acid
CLA minus
oleic acid
CLA minus
Industrial trans 2
Mean 6 SD Mean 6 SD Mean 6 SD Mean 6 SD
Change 3
(95% CI)
Change 3
(95% CI)
Change 3
(95% CI)
mmol/L
Total cholesterol 4.4260.70 4.7760.75 4.7260.75 4.6260.82 0.31 4 0.20 4 20.10 6
(0.22 to 0.39) (0.11 to 0.30) (20.20 to 20.01)
HDL-cholesterol 1.3160.29 1.2860.29 1.2660.29 1.2560.30 20.05 4 20.06 4 0.00
(20.08 to 20.03) (20.09 to 20.03) (20.03 to 0.03)
LDL-cholesterol 2.6860.62 3.0260.66 3.0060.66 2.9260.70 0.31 4 0.23 4 20.08 6
(0.24 to 0.38) (0.16 to 0.31) (20.15 to 0.00)
Total to HDL ratio 3.4860.75 3.8860.89 3.8960.89 3.8360.92 0.40 4 0.35 4 20.06
(0.32 to 0.49) (0.25 to 0.44) (20.15 to 0.04)
LDL to HDL ratio 2.1460.68 2.4860.78 2.5060.78 2.4460.78 0.35 4 0.30 4 20.05
(0.28 to 0.43) (0.22 to 0.38) (20.13 to 0.03)
Triglycerides 0.9360.33 1.0560.41 1.0860.41 0.9960.42 0.15 4 0.05 20.10 5
(0.09 to 0.21) (20.01 to 0.12) (20.16 to 20.03)
mg/dl
Apo-B 70.8614.6 78.2615.7 76.0615.7 74.1616.5 5.2 4 3.3 4 21.9 6
(3.5 to 6.9) (1.6 to 5.1) (23.6 to 20.1)
ApoB to LDL ratio 266628 261627 256627 256627 210.4 4 29.9 4 0.5
(215.3 to 25.6) (214.6 to 25.2) (24.1 to 5.2)
1The subjects consumed each diet for 3 weeks each, in random order.
2Levels on industrial trans fatty acids were recalculated to correct for the slightly higher intake of saturated and the slightly lower intake of total trans and cis fatty acids
on the industrial trans diet than on the CLA diet. Corrections were made using the equations of Mensink et al. [16].
3Variables were analyzed with a mixed linear model, with diet as the repeated factor within subjects and period as a fixed effect. P,0.05 was considered to be a
significant effect. When significant, Least Significant Differences t-test procedure was used for pair wise comparisons:
4p,0.001.
5p,0.015.
6p,0.05.
doi:10.1371/journal.pone.0009000.t004
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acids. The statistical power was high and the confidence intervals
of the outcomes were narrow (Table 4). Lack of power caused by
the use of low doses is a likely explanation why previous studies
have failed to detect the effect of CLA on HDL and LDL-
cholesterol unambiguously [28,29]. Our use of both a cis-
monounsaturated and an industrial trans fatty acid diet facilitate
comparison of our outcomes with those of other studies. Finally,
we employed both male and female volunteers.
Our study also had limitations. First, we fed doses of trans
fatty acids which cannot be reached with a normal diet. We used
a high intake of CLA because otherwise the number of subjects
needed to define the outcomes with sufficient precision would
have become prohibitive. At an intake of 3.6 grams per day
(,1.3% energy), which was typical in previous studies, we would
have needed 617 volunteers to obtain a significant effect of CLA
on LDL-cholesterol. Second, our treatments lasted only 3 weeks.
Effects of other fatty acids on lipid and lipoprotein levels stabilize
within 2 weeks after a change in dietary fatty acids [30,31], but
the long-term effects of CLA might still differ from what we
found in this trial. Third, the CLA diet did not contain pure cis-
9, trans-11 CLA but also 1.5% of energy (4.4 g/d) as trans-10, cis-
12 CLA. It has been suggested that the latter has a more
unfavorable effect on blood lipids than the cis-9, trans-11 CLA
found in ruminant fats [32]. However, this has not been
confirmed in other studies [28,29]. The effect of the ruminant
cis-9, trans-11 CLA isomer may be less than suggested by our
data because of the presence of trans-10, cis-12 CLA, but it is
unlikely that the entire effect of the CLA oil was due to the
relative small amount of trans-10, cis-12 CLA. Finally, our
subjects were young, lean and healthy. Studies of industrial trans
fatty acids yielded similar effects on blood lipids in different
populations, but still the effect of CLA on lipid and lipoprotein
levels seen here needs verification in the elderly and in patients at
risk for cardiovascular disease.
Comparison with Previous Studies
Previous studies of CLA mostly compared the effects of
approximately 3.6 grams of CLA per day with a placebo, with no
control of food intake. Effects on lipids and lipoprotein levels
were mostly not significant [28,29,33–41]. However, closer
inspection shows that most of these studies observed an increase
of the LDL to HDL cholesterol ratio, even though that effect
failed to reach statistical significance (Brouwer et al., submitted).
Controlled diets high in CLA were provided in two studies.
Desroches et al. found that butter high in CLA and other natural
trans fatty acids significantly raised plasma cholesterol and the
LDL to HDL cholesterol ratio relative to control butter [12]. A
similar study from Tricon et al. [13] also found a small but
significant rise in the LDL to HDL cholesterol ratio on dairy
products high versus low in CLA and other dairy trans fatty acids.
In both studies, some 60 to 80% of the animal trans consisted not
of CLA but of vaccenic acid (trans-11 18:1), a trans fatty acid also
found in partially hydrogenated industrial fats. Our study shows
that cis-9, trans-11 CLA, which is exclusively found in milk and
body fat of ruminant animals, accompanied by a smaller dose of
trans-10, cis-12 CLA, also raises the LDL to HDL cholesterol
ratio.
In our study, men showed greater responses of some lipids and
lipoproteins to both CLA and to industrial trans fatty acids than
women. In contrast, the TRANSFACT trial, a study comparing
ruminant trans fatty acids with industrial trans fatty acids, found
a greater response to ruminant trans fatty acids in women than in
men [27]. Other trials found no differences between men and
women in the response of blood lipids to industrial trans fatty
acids [42]. Both the larger effect in men seen in our study and the
smaller effect seen in the TRANSFACT study may therefore be
due to chance. We could also assume separate physiologic
mechanisms between men and women in response to both CLA
and industrial trans fatty acids. These hypothetical mechanisms
would cause CLA to have a larger effect and would cause the
ruminant trans fatty acids used in TRANSFACT to have a
smaller effect on blood lipids in men than in women. However, in
view of the sparsity of data we would rather invoke chance
fluctuations than a multitude of mechanisms with opposite
actions.
Clinical Relevance
The effect of CLA provided by usual intakes of milk and meat
on blood lipids is negligibly small even if it lowers HDL- and raise
LDL-cholesterol to the extent predicted by our study. Mozaffarian
et al. [5] calculated that increasing trans fatty intake by 1% of
energy increases the risk of cardiovascular disease by 3 to 12%.
The average dietary intake of 0.3 g of cis-9, trans-11 CLA a day, or
0.1% of energy, in Europe [43,44] would then increase the risk of
cardiovascular disease by only 0.3 to 1.2%.
Much higher amounts of CLA are taken in the form of
supplements. An intake of 3 g/day of a CLA mixture, as
recommended by manufacturers of CLA supplements, could
theoretically increase the risk of cardiovascular disease by 3 to
12%. CLA supplements should therefore have clear-cut other
health benefits to justify their intake. At present, these benefits
have not been firmly established. Moreover, recent changes in
dairy cattle feeding have led to milk with a lower content of
saturated fatty acids and a higher content of cis-9, trans-11 CLA
and other dairy trans fats [45]. Our data suggest that the effect of
these changes on heart disease risk in consumers of milk and meat
fat are at the very least equivocal.
Conclusion
Our results indicate that a high intake of cis-9, trans-11 CLA, a
trans fatty acid largely restricted to milk and meat, plus a smaller
amount of trans-10, cis-12 CLA raises LDL- and lowers HDL-
cholesterol in humans. The effect of CLA on the LDL to HDL
cholesterol ratio and the total to HDL cholesterol ratio is
comparable with that of the artificial trans fatty acids that arise
during industrial hydrogenation of vegetable oils.
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